{"id":"avtx-009-regimen-2","safety":{"commonSideEffects":[{"rate":null,"effect":"unknown"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AVTX-009 Regimen 2 works by binding to the molecular target, which results in the desired therapeutic effect.","oneSentence":"AVTX-009 Regimen 2 is a small molecule that targets the molecular target.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:30:08.394Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"unknown"}]},"trialDetails":[{"nctId":"NCT06603077","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Avalo Therapeutics, Inc.","startDate":"2024-09-16","conditions":"Hidradenitis Suppurativa","enrollment":250}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":523,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AVTX-009 Regimen 2","genericName":"AVTX-009 Regimen 2","companyName":"Avalo Therapeutics, Inc.","companyId":"avalo-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AVTX-009 Regimen 2 is a treatment being studied in a clinical trial for patients with moderate to severe Hidradenitis Suppurativa. AVTX-009 Regimen 2 is a small molecule intervention.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}